Gilead Science Corporation said on Wednesday it was “aware of positive statements” graduating from the Institute of Allergy and Infectious Diseases for its therapeutic experiments with a remdisfer serum for the treatment of corona virus.
The company said in a brief statement: “We understand that the clinical trials have reached their initial end, and the institute will provide us with details through a future notification.
Gilead’s treatment has not received any approval from anywhere, but is promoted as promising and effective in healing the Coronavirus.